JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $75

JP Morgan analyst Tessa Romero has maintained an Overweight rating on Cytokinetics (NASDAQ: CYTK) and raised the price target from $74 to $75. This adjustment reflects the firm's positive outlook on the company's performance.